IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 67.27

Change

+1.39 (+2.11)%

Market Cap

N/A

Volume

0.10M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-13 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.82 (+1.30%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

+0.84 (+1.27%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+1.50 (+1.42%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+0.21 (+0.23%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.63 (-2.79%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.52 (-1.66%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+2.03 (+2.18%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.03 (+0.11%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.49 (+0.81%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.58 (-2.56%)

USD 8.55M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.36% 52% F 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.36% 52% F 85% B
Trailing 12 Months  
Capital Gain 5.01% 67% D+ 54% F
Dividend Return 1.45% 94% A 23% F
Total Return 6.46% 71% C- 48% F
Trailing 5 Years  
Capital Gain 22.50% 48% F 63% D
Dividend Return 8.62% 95% A 26% F
Total Return 31.12% 67% D+ 58% F
Average Annual (5 Year Horizon)  
Capital Gain 4.30% 48% F 48% F
Dividend Return 5.68% 52% F 45% F
Total Return 1.38% 100% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 15.39% 71% C- 66% D+
Risk Adjusted Return 36.92% 67% D+ 51% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike